Skip to main content

Biofrontera, Inc. (BFRI)

Biofrontera will go public soon. The estimated IPO date is October 21, 2021.
Stock Price: $5.00 - $7.00
Current IPO price range
Chart not available yet
Market Cap66.00M
Revenue (ttm)18.97M
Net Income (ttm)-10.42M
Shares Out11.00M
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About BFRI

Biofrontera is a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Our principal product is Ameluz®, which is a prescription drug approved for use in combination with our licensor’s medical device, the BF-RhodoLED® lamp, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate se...

IndustryPharmaceutical Preparations
IPO DateOct 21, 2021
CEOErica Monaco, CPA
Employees56
Stock ExchangeNASDAQ
Ticker SymbolBFRI
Full Company Profile

Financial Performance

In 2020, Biofrontera's revenue was $18.85 million, a decrease of -28.01% compared to the previous year's $26.18 million. Losses were -$10.99 million, 0.05% more than in 2019.

Financial Statements

News

Biofrontera IPO Registration Document (S-1)

Biofrontera, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC